A small proportion of human subjects are known to express soluble B7-1.39 Since Ipilimumab blocks the interaction between soluble CD80 and CTLA-4, it is of interest to consider whether blocking soluble CD80 may be responsible for tumor rejection. The gene discussed is CTLA4; the disease is neoplasm.